Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Recently published results from a Phase 1 trial conducted by ONCOtherapeutics among 28 heavily previously treated MM patients administered RUX, lenalidomide (LEN) and MP demonstrated that the therapy was well tolerated and RUX overcame refractoriness to ...
Brand Name : Jakafi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2022
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Incyte Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Recently published results from a Phase 1 trial for 28 heavily previously treated MM patients administered Ruxolitinib, lenalidomide and methylprednisolone demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroi...
Brand Name : Jakafi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2021
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Incyte Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?